Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Abbott, AstraZeneca cholesterol combo

Executive Summary

Abbott and AstraZeneca have decided to pursue development of a combination of Abbott's next-generation fenofibrate ABT-335 with AstraZeneca's Crestor (rosuvastatin), the firms announce Aug. 31. The partnership to develop a multi-targeted fenofibrate/statin cholesterol combination was announced last year. However, the companies had not determined whether the product would use the investigational ABT-335 or Abbott's marketed drug, TriCor (fenofibrate). Abbott and AstraZeneca are targeting 2009 for submitting an NDA for the combination, which is expected to offer the LDL-C lowering benefits of Crestor and the HDL-C raising and triglyceride-lowering benefits of fibrates. Based on positive clinical trial results, Abbott also said it will file ABT-335 as monotherapy by year-end...
Advertisement

Related Content

Advertisement
UsernamePublicRestriction

Register

PS048734

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel